{
    "id": 7209,
    "fullName": "PDGFRA T674I",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "PDGFRA T674I lies within the protein kinase domain of the Pdgfra protein (UniProt.org). T674I has been demonstrated to occur as a secondary resistance mutation in the context of FIP1L-PDGFRA (PMID: 12660384, PMID: 16754777), but has not been biochemically characterized and therefore, its effect on Pdgfra protein function is unknown (PubMed, Mar 2020).",
            "references": [
                {
                    "id": 2988,
                    "pubMedId": 12660384,
                    "title": "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12660384"
                },
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 14732,
                    "pubMedId": 16754777,
                    "title": "The FIP1L1-PDGFRA T674I mutation can be inhibited by the tyrosine kinase inhibitor AMN107 (nilotinib).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16754777"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5156,
        "geneSymbol": "PDGFRA",
        "terms": [
            "PDGFRA",
            "CD140A",
            "PDGFR-2",
            "PDGFR2"
        ]
    },
    "variant": "T674I",
    "createDate": "06/08/2015",
    "updateDate": "03/02/2020",
    "referenceTranscriptCoordinates": {
        "id": 119048,
        "transcript": "NM_006206",
        "gDna": "chr4:g.54278380C>T",
        "cDna": "c.2021C>T",
        "protein": "p.T674I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2360,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I study, an acute myeloid leukemia patient harboring FIP1L1-PDGFRA and a PDGFRA T674I secondary mutation demonstrated resistance to Gleevec (imatinib) (PMID: 18843283, PMID: 12660384).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 770,
                "therapyName": "Imatinib",
                "synonyms": null
            },
            "indication": {
                "id": 9119,
                "name": "acute myeloid leukemia",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2988,
                    "pubMedId": 12660384,
                    "title": "A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12660384"
                },
                {
                    "id": 2990,
                    "pubMedId": 18843283,
                    "title": "Five years since the discovery of FIP1L1-PDGFRA: what we have learned about the fusion and other molecularly defined eosinophilias.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18843283"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11470,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Nexavar (sorafenib) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11473,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Iressa (gefitinib) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 751,
                "therapyName": "Gefitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17277,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing PDGFRA T674I in the context of the FIP1L1-PDGFRA fusion demonstrated resistance to growth inhibition by Tasigna (nilotinib) in culture (PMID: 16030188).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 829,
                "therapyName": "Nilotinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 15308,
                    "pubMedId": 16030188,
                    "title": "The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16030188"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17278,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Nexavar (sorafenib) in culture, demonstrating decreased cell viability (PMID: 16645167).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14731,
                    "pubMedId": 16645167,
                    "title": "Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16645167"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11471,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Votrient (pazopanib) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 848,
                "therapyName": "Pazopanib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11474,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Tarceva (erlotinib) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 4,
                "therapyName": "Erlotinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11472,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Dovitinib (TKI258) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 721,
                "therapyName": "Dovitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11469,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed cells expressing FIP1L1-PDGFRA and PDGFRA T674I were sensitive to Sutent (sunitinib) in culture, demonstrating decreased cell viability (PMID: 26776524).",
            "molecularProfile": {
                "id": 7079,
                "profileName": "FIP1L1 - PDGFRA PDGFRA T674I"
            },
            "therapy": {
                "id": 930,
                "therapyName": "Sunitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9508,
                    "pubMedId": 26776524,
                    "title": "Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26776524"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7078,
            "profileName": "PDGFRA T674I",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 7079,
            "profileName": "FIP1L1 - PDGFRA PDGFRA T674I",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 119053,
            "transcript": "XM_011534385",
            "gDna": "chr4:g.54278380C>T",
            "cDna": "c.2021C>T",
            "protein": "p.T674I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 119049,
            "transcript": "XM_006714041",
            "gDna": "chr4:g.54277950C>T",
            "cDna": "c.2021C>T",
            "protein": "p.T674I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 119051,
            "transcript": "XM_017008282",
            "gDna": "chr4:g.54278380C>T",
            "cDna": "c.2021C>T",
            "protein": "p.T674I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 119052,
            "transcript": "XM_005265743",
            "gDna": "chr4:g.54278380C>T",
            "cDna": "c.2021C>T",
            "protein": "p.T674I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 119048,
            "transcript": "NM_006206",
            "gDna": "chr4:g.54278380C>T",
            "cDna": "c.2021C>T",
            "protein": "p.T674I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 119050,
            "transcript": "XM_006714039",
            "gDna": "chr4:g.54277950C>T",
            "cDna": "c.2021C>T",
            "protein": "p.T674I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}